ArticleAIDS and behavior2025
Preference for Long-Acting HIV Prevention Methods Among Transgender Women Vulnerable to HIV in Eastern and Southern United States: Findings from the LITE Study.
Article in AIDS and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- HIV Preexposure Prophylaxis Utilization and Reasons for Never Using Preexposure Prophylaxis Among Transfeminine Persons in the United States: Findings From the Transgender Women's Internet Survey and Testing (TWIST) Study.Open forum infectious diseases · 2026Article
- Preference for Long-Acting Injectable PrEP Compared With Daily Oral PrEP Among Transgender Women in the U.S.: Findings From a Multisite Cohort.AJPM focus · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
Abstract
HIV incidence among transgender women remains high and disproportionately impacts young, Black, and Latina transgender women. Data on preferred PrEP modalities among this population are limited. Participants in The LITE Cohort completed a survey module on PrEP modality preferences during 24-month study visits. We summarized ranked preferences based on an exhaustive set of 10 head-to-head comparisons of 5 PrEP modalities (pill, injection, implantable device, topical gel, and intravenous antibodies) and conducted in-depth interviews to contextualize findings. Between 2020 and 2022, 789 participants completed the PrEP modality survey module. The most preferred PrEP modality was the implant (ranked first among 45% of respondents), followed by pill (21%), injection (19%), gel (10%), and intravenous antibodies (4%). The implant ranked highest among Latina transgender women (36%), young adult transgender women (ages 18-24 years; 41%), those living in the South (47%), and those with PrEP indication(s) (45%), while injection was the top-ranked modality among Black transgender women (30%). Qualitative analysis of in-depth interviews (n = 45) revealed that PrEP modality preferences were individualized, context-dependent, considered gender-related factors (e.g. gender-affirming hormone injections), and informed by prior healthcare experiences, personal values, and anticipated modality-specific facilitators and barriers. Our findings suggest high interest in long-acting PrEP options, including implants and injections, and daily pills among transgender women.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.